Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy.
We conducted a randomized, open-label, controlled trial to assess the efficacy of oxcarbazepine for prophylaxis against oxaliplatin-induced peripheral neuropathy (OxIN). Thirty-two patients with colon cancer received 12 courses of the FOLFOX-4 regimen and were randomly assigned to receive oxcarbazepine (600 mg BID) or chemotherapy without oxcarbazepine. The incidence of OxIN was strikingly decreased in patients receiving oxcarbazepine (31.2% vs 75%). Oxcarbazepine may prevent OxIN symptoms. Further larger placebo-controlled trials are warranted to confirm our results.
Argyriou
A A
AA
Neurology Department, EMG/ENG Laboratory, University of Patras Medical School, 26504, Rion-Patras, Greece. andargyriou@yahoo.gr
Chroni
E
E
Polychronopoulos
P
P
Iconomou
G
G
Koutras
A
A
Makatsoris
T
T
Gerolymos
M K
MK
Gourzis
P
P
Assimakopoulos
K
K
Kalofonos
H P
HP
D000368:Aged; D000927:Anticonvulsants / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000188:drug therapy; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000008:administration & dosage; D009944:Organoplatinum Compounds / Q000009:adverse effects*; D000077150:Oxaliplatin; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000517:prevention & control*; D016896:Treatment Outcome
D000927:Anticonvulsants; D000970:Antineoplastic Agents; D004338:Drug Combinations; D018696:Neuroprotective Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin